cefaclor anhydrous has been researched along with Infections, Staphylococcal Skin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akashi, S; Arai, I; Hashimoto, Y; Kaneda, Y; Nakaike, S; Takahashi, N | 1 |
| Hanfling, MJ; Hausinger, SA; Squires, J | 1 |
1 trial(s) available for cefaclor anhydrous and Infections, Staphylococcal Skin
| Article | Year |
|---|---|
Loracarbef vs. cefaclor in pediatric skin and skin structure infections.
Topics: Cefaclor; Cephalosporins; Child; Child, Preschool; Double-Blind Method; Female; Haemophilus Infections; Haemophilus influenzae; Humans; Infant; Male; Skin Diseases, Infectious; Staphylococcal Skin Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes | 1992 |
1 other study(ies) available for cefaclor anhydrous and Infections, Staphylococcal Skin
| Article | Year |
|---|---|
Clarithromycin inhibits the development of dermatitis in NC/Nga mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Cefaclor; Clarithromycin; Dermatitis, Atopic; Dexamethasone; Histocompatibility Antigens Class II; Immunosuppressive Agents; Male; Mast Cells; Mice; Mice, Inbred Strains; Skin; Staphylococcal Skin Infections; Staphylococcus aureus; Time Factors | 2003 |